Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

TL;DR: Of the several treatment strategies aiming to abolish the immune cell imbalance in PDAC, and targeting the immune system, DCs manipulation, vaccination with tumor derived antigens and Treg depletion appear to be of benefit, but still require validation before being recommended in the clinical setting.

TL;DR: The current literature on rheumatic and musculoskeletal IRAEs is summarized and the incidence, clinical presentations, and treatment considerations are highlighted.

TL;DR: Durable long-term responses in some patients with advanced melanoma, initially with ipilimumab and more recently antibodies targeting either PD-1 or PD-L1 in patients with melanoma and renal cancer, non-small-cell lung, bladder and head and neck cancers with less toxicity, have provided real optimism that immunotherapeutic approaches can improve outcomes in a wide range of cancer.

TL;DR: In adjuvant setting in patients with resected metastases AGI-101H combined with surgery of recurring disease demonstrated long-term survival and is a good candidate for combinatorial treatment with immune check-points inhibitors or tumor hypoxia normalizators.

TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.

TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.

TL;DR: FOLFIRINOX was associated with a survival advantage and had increased toxicity as compared with gemcitabine, and is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.

TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.